Logo

KURA

Kura Oncology, Inc.

KURA

Kura Oncology, Inc. • NASDAQ
$12.14 ▲ 1.25% (+0.15)
Market Cap $1.06 B
52w High $12.49
52w Low $5.41
Dividend Yield 0%
P/E -4.9
Volume 476.80K
Outstanding Shares 87.02M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $20.75M ▲ $97.535M ▲ $-74.116M ▼ -357.186% ▲ $-0.85 ▼ $-73.952M ▼
Q2-2025 $15.288M ▲ $87.954M ▲ $-66.122M ▼ -432.509% ▼ $-0.75 ▼ $-65.507M ▼
Q1-2025 $14.108M ▼ $78.808M ▲ $-57.429M ▼ -407.067% ▼ $-0.66 ▼ $-64.7M ▼
Q4-2024 $53.883M ▲ $76.338M ▲ $-19.217M ▲ -35.664% ▼ $-0.22 ▲ $-16.592M ▲
Q3-2024 $0 $59.884M $-54.404M 0% $-0.63 $-53.784M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $549.665M ▼ $649.381M ▼ $406.839M ▲ $242.542M ▼
Q2-2025 $630.728M ▼ $682.425M ▼ $376.939M ▼ $305.486M ▼
Q1-2025 $658.191M ▼ $743.764M ▼ $379.358M ▲ $364.406M ▼
Q4-2024 $727.395M ▲ $760.159M ▲ $346.519M ▲ $413.64M ▼
Q3-2024 $455.297M $478.837M $55.066M $423.771M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-74.116M ▼ $-80.627M ▼ $93.966M ▲ $0 ▼ $13.339M ▼ $-83.194M ▼
Q2-2025 $-66.122M ▼ $-28.777M ▲ $58.941M ▲ $515K ▲ $30.679M ▲ $-30.235M ▲
Q1-2025 $-57.429M ▼ $-71.927M ▼ $-101.409M ▼ $143K ▼ $-173.193M ▼ $-72.219M ▼
Q4-2024 $-19.217M ▲ $269.131M ▲ $-94.955M ▼ $806K ▼ $174.982M ▲ $268.759M ▲
Q3-2024 $-54.404M $-43.44M $45.535M $2.202M $4.297M $-43.44M

Five-Year Company Overview

Income Statement

Income Statement Kura is still very much a development‑stage biotech from a revenue perspective. Commercial sales have only just started to appear and are still tiny relative to expenses, so the company continues to run at sizable operating and net losses every year. Those losses have gradually increased over time as clinical programs and commercialization efforts have scaled up. Earnings per share remain deeply negative, which is typical for a clinical‑stage oncology company building out late‑stage trials and an initial commercial infrastructure, but it does mean the business is still far from covering its cost base with product revenue.

Balance Sheet

Balance Sheet The balance sheet shows a classic biotech profile: strong reliance on equity, very little debt, and a large cash balance that moves up and down with capital raises and partnership inflows. Cash and total assets had been trending down for several years, then rebounded meaningfully in the most recent period, likely from new financing and/or collaboration payments. Shareholders’ equity has been eroded by years of losses but stabilized recently, suggesting fresh capital offsetting the burn. Overall leverage is low, which reduces financial risk, but the company still depends on external funding or future product cash flows to sustain operations over the long term.

Cash Flow

Cash Flow Historically, Kura has burned cash from operations, reflecting heavy R&D and limited revenue. In the latest year, operating and free cash flow turned positive, a notable shift that likely reflects one‑time or lumpy cash inflows (for example, from a partnership or upfront payment) rather than a fully self‑funding business. Capital spending needs are minimal, so the main driver of cash use is R&D and commercialization expense. The improved recent cash flow buys time and financial flexibility, but without steady product revenue, cash generation remains uncertain and could revert if milestone or financing activity slows.

Competitive Edge

Competitive Edge Kura occupies a focused niche in precision oncology, concentrating on specific genetic subtypes of cancer rather than broad, crowded tumor markets. Its lead menin inhibitor, ziftomenib, already has an FDA approval in a defined segment of acute myeloid leukemia, giving Kura first‑mover or early‑mover status in that genetic niche. The company also leads in a revived area of farnesyl transferase inhibition, where its biomarker‑driven strategy distinguishes it from past, less selective efforts. That said, competition is emerging, especially in menin inhibition, and larger oncology players could intensify pressure over time. Kura’s advantage rests on focused indications, clinical differentiation, and a partner network rather than sheer scale.

Innovation and R&D

Innovation and R&D The core of Kura’s value is its R&D engine around two mechanisms: menin inhibition and farnesyl transferase inhibition. Ziftomenib shows how the company uses genetic markers to target patients most likely to benefit, and it is being pushed into earlier treatment lines and combinations, which could broaden its impact if data hold up. Tipifarnib and the next‑generation FTI KO‑2806 aim to unlock previously underexploited biology, especially when combined with other targeted therapies to address resistance. A strong patent portfolio, ongoing work on next‑generation menin inhibitors, and a strategy of combination trials all point to a long R&D runway. The flip side is that pipeline success is inherently uncertain and expensive, and clinical setbacks in any of these key programs would be meaningful.

Summary

Kura Oncology is transitioning from a pure clinical‑stage biotech toward an emerging commercial oncology company, but the financials still look like an R&D‑driven story: minimal revenue, sizable recurring losses, and dependence on external capital and partnership inflows. The balance sheet is relatively clean, with little debt and a recently strengthened cash position, which helps support ongoing trials and the early launch of its first approved drug. The company’s competitive edge lies in targeted precision oncology, niche genetic indications, and a robust IP and partnership framework, offset by growing competition in its core mechanisms and typical biotech development risk. Overall, Kura’s trajectory will hinge on the commercial uptake and label expansion of ziftomenib and on whether its FTI and next‑generation menin programs can translate promising science into durable, real‑world clinical and financial outcomes.

NEWS

November 25, 2025 · 5:16 PM UTC

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Read more

November 13, 2025 · 10:51 AM UTC

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Read more

November 12, 2025 · 4:05 PM UTC

Kura Oncology to Participate in Upcoming Investor Conference

Read more

November 7, 2025 · 7:30 AM UTC

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 4, 2025 · 6:31 AM UTC

Kura Oncology Reports Third Quarter 2025 Financial Results

Read more